Destiny Pharma PLC Participating in Cantor Antibiotics Summit panel
11 January 2018 - 6:00PM
RNS Non-Regulatory
TIDMDEST
Destiny Pharma PLC
11 January 2018
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Destiny Pharma to participate in panel discussion at the Cantor
Antibiotics Summit
Brighton, United Kingdom - 11 January 2018 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development of novel anti-microbial drugs, which address the global
problem of anti-microbial resistance (AMR), announces that Dr Bill
Love, Chief Scientific Officer and Founder of Destiny Pharma, will
participate in the panel discussion titled 'Novel Ways to Treat
and/or Address Infections' at the Cantor Antibiotics Summit on
Wednesday 17 January 2018 at 12:15pm EST at the Omni Berkshire
Hotel, 21 East 52nd Street, New York, NY 10022.
The Cantor Antibiotics Summit, hosted by Cantor Fitzgerald, will
bring together leading antibiotic companies to discuss novel ways
to treat infections, what will drive the uptake of these new
products, and important catalysts to look forward to in 2018.
For further information, please contact:
Destiny Pharma
Neil Clark, CEO
Simon Sacerdoti, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell / Hanna Skeppner
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Broker)
Philip Davies / Will Goode, Corporate Finance
pdavies@cantor.co.uk
+44 (0)20 7894 8337
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative
biotechnology company focused on the development of novel medicines
that represent a new approach to the treatment of infectious
disease. These potential new medicines are being developed to
address the need for new drugs for the prevention and treatment of
life-threatening infections caused by antibiotic-resistant
bacteria, often referred to as "superbugs". Tackling anti-microbial
resistance has become a global imperative recognised by the WHO and
the United Nations, as well as the G7 and the G20 countries. For
further information, please visit https://www.destinypharma.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABUGDBLGBBGIG
(END) Dow Jones Newswires
January 11, 2018 02:00 ET (07:00 GMT)
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Apr 2024 to May 2024
Destiny Pharma (LSE:DEST)
Historical Stock Chart
From May 2023 to May 2024